Analysis and progress of peptide and protein biomarker methodology for myocardial injury

doi:10.3969/j.issn.1673-8640.2023.08.015

Abstract

Abstract:

The prevalence of myocardial injury diseases is increasing rapidly in the world. Monitoring and accurate diagnosis of myocardial injury diseases is essential to reduce disease hazard. Currently，the biomarkers in myocardial injury mainly belong to peptides and proteins，typically expressed lower than 10^-8 g/L. Immunoassay-based techniques enable a sensitive determination level for low abundant biomarkers，followed by developed as the dominant method. However，some inherent problems have also existed among current clinical immunoassays regarding testing accuracy. To illustrate testing barriers，this review proposes and summarizes some representative issues that usually interfere with the testing accuracy in B-type natriuretic peptide（BNP） and troponin. Meanwhile，some emerging technologies will be introduced in the context，and then to discuss its application that potential applied in myocardial injury clinical measurement.

Key words: Biomarker, Myocardial injury, Clinical determination, Emerging technology

CLC Number:

R446.1

SUN Zepeng, WANG Hongbin, WANG Jiandong, SONG Dewei, XIAO Peng. Analysis and progress of peptide and protein biomarker methodology for myocardial injury[J]. Laboratory Medicine, 2023, 38(8): 784-789.

Figures/Tables 3

References 22

[1]	REED G W, ROSSI J E, CANNON C P. Acute myocardial infarction[J]. Lancet, 2017, 389(10065):197-210. DOI PMID
[2]	HALLWORTH M J. The '70% claim':what is the evidence base?[J]. Ann Clin Biochem, 2011, 48(Pt 6):487-488. DOI URL
[3]	LADUE J S, WROBLEWSKI F, KARMEN A. Serum glutamic oxaloacetic transaminase activity in human acute transmural myocardial infarction[J]. Science, 1954, 120(3117):497-499. DOI PMID
[4]	段天兵, 向定成. 2019年急性心肌损伤标志物研究进展[J]. 中华心血管病杂志(网络版), 2020, 3(1):1-6.
[5]	SMITH J G, GERSZTEN R E. Emerging affinity-based proteomic technologies for large-scale plasma profiling in cardiovascular disease[J]. Circulation, 2017, 135(17):1651-1664. DOI PMID
[6]	APPLE F S. Counterpoint:standardization of cardiac troponin I assays will not occur in my lifetime[J]. Clin Chem, 2012, 58(1):169-171. DOI URL
[7]	张妍, 王薇, 何法霖, 等. 全国150家实验室心肌损伤标志物参考区间来源及决定限的分布[J]. 中华心血管病杂志, 2014, 42(3):193-196.
[8]	KATRUKHA A G, BEREZNIKOVA A V, ESAKOVA T V, et al. Troponin I is released in bloodstream of patients with acute myocardial infarction not in free form but as complex[J]. Clin Chem, 1997, 43(8 Pt 1):1379-1385. PMID
[9]	CHRISTENSON R H, DUH S H, APPLE F S, et al. Toward standardization of cardiac troponin I measurements part Ⅱ:assessing commutability of candidate reference materials and harmonization of cardiac troponin I assays[J]. Clin Chem, 2006, 52(9):1685-1692. DOI URL
[10]	CLERICO A, ZANINOTTO M, PRONTERA C, et al. State of the art of BNP and NT-proBNP immunoassays:the CardioOrmoCheck study[J]. Clin Chim Acta, 2012, 414:112-119. DOI URL
[11]	VASILE V C, JAFFE A S. Natriuretic peptides and analytical barriers[J]. Clin Chem, 2017, 63(1):50-58. DOI PMID
[12]	YANDLE T G, RICHARDS A M. B-type natriuretic peptide circulating forms:analytical and bioactivity issues[J]. Clin Chim Acta, 2015, 448:195-205. DOI URL
[13]	LEWIS L K, RAUDSEPP S D, YANDLE T G, et al. Development of a BNP1-32 immunoassay that does not cross-react with proBNP[J]. Clin Chem, 2017, 63(6):1110-1117. DOI PMID
[14]	WANG Z, ZONG S, WU L, et al. SERS-activated platforms for immunoassay:probes,encoding methods,and applications[J]. Chem Rev, 2017, 117(12):7910-7963. DOI URL
[15]	HE Y, WANG Y, YANG X, et al. Metal organic frameworks combining CoFe2O4 magnetic nanoparticles as highly efficient SERS sensing platform for ultrasensitive detection of N-terminal pro-brain natriuretic peptide[J]. ACS Appl Mater Interfaces, 2016, 8(12):7683-7690. DOI URL
[16]	MATHUR A, KELSO D M. Multispectral image analysis of binary encoded microspheres for highly multiplexed suspension arrays[J]. Cytometry A, 2010, 77(4):356-365.
[17]	LIU N, ZHENG F, ZHENG X. Detection of biomarkers of acute myocardial infarction by high-throughput suspension array technology in serum sample[J]. Bioanalysis, 2018, 10(1):47-58. DOI PMID
[18]	COHEN L, WALT D R. Highly sensitive and multiplexed protein measurements[J]. Chem Rev, 2019, 119(1):293-321. DOI PMID
[19]	JAROLIM P, PATEL P P, CONRAD M J, et al. Fully automated ultrasensitive digital immunoassay for cardiac troponin I based on single molecule array technology[J]. Clin Chem, 2015, 61(10):1283-1291. DOI PMID
[20]	YAN V Z, THOMAS J. 质谱技术在临床实验室的应用[J]. 检验医学, 2019, 34(1):1-7.
[21]	TORMA A F, GROVES K, BIESENBRUCH S, et al. A candidate liquid chromatography mass spectrometry reference method for the quantification of the cardiac marker 1-32 B-type natriuretic peptide[J]. Clin Chem Lab Med, 2017, 55(9):1397-1406. DOI PMID
[22]	DEITRICH C L, CUELLO-NUÑEZ S, KMIOTEK D, et al. Accurate quantification of selenoprotein P(SEPP1) in plasma using isotopically enriched seleno-peptides and species-specific isotope dilution with HPLC coupled to ICP-MS/MS[J]. Anal Chem, 2016, 88(12):6357-6365. DOI URL